Dr. Reddy’s receives EIR from USFDA
Dr Reddy’s Laboratories Ltd has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (FDA) for Srikakulam formulations plant unit I, indicating closure of the audit.
The inspection classification of this facility is determined as “No Action Indicated” (NAI). Dr Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
Also read” EU GMP Certification for Biocon
The company’s therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.